

HR 6980

To direct the Secretary of Health and Human Services to conduct a pilot program under which the Secretary increases the conduct of unannounced inspections of foreign human drug establishments and evaluates the differences between inspections of domestic and foreign human drug establishments, including the impact of announcing inspections to persons who own or operate foreign human drug establishments in advance of an inspection.

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Mar 8, 2022

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Mar 9, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/6980>

Sponsor

Name: Rep. Hudson, Richard [R-NC-8]

Party: Republican • **State:** NC • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Eshoo, Anna G. [D-CA-18]	D · CA		Mar 8, 2022

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Mar 9, 2022

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 HR 7667	Related bill	Jun 9, 2022: Received in the Senate.
117 S 3799	Related bill	Mar 15, 2022: Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.

Summary (as of Mar 8, 2022)

This bill requires the Food and Drug Administration to conduct a pilot program to increase the number of unannounced inspections of foreign drug manufacturing facilities and evaluate the differences between inspections of domestic and foreign facilities.

Actions Timeline

- **Mar 9, 2022:** Referred to the Subcommittee on Health.
- **Mar 8, 2022:** Introduced in House
- **Mar 8, 2022:** Referred to the House Committee on Energy and Commerce.